Xcenda LLC, Carrollton, Texas, USA
Xcenda LLC, Carrollton, Texas, USA.
Lupus Sci Med. 2022 May;9(1). doi: 10.1136/lupus-2021-000640.
SLE is a chronic, multiorgan, autoimmune disease; however, current prevalence estimates are dated and often from non-generalisable patient populations, and quality of life and patient-reported outcomes in the real-world SLE population are not well-published. The present study used the Medical Expenditure Panel Survey (MEPS), a generalisable US data source encompassing a representative sample of regions/payers, to estimate SLE prevalence and characterise disease burden compared with non-SLE respondents.
Retrospective population-based survey data weighted to the full US population from MEPS for the calendar years 2016-2018, pooled over the full study period, was used. The primary inclusion criteria included adults with self-reported SLE and either a record of SLE-related medication and/or rheumatologist visit in the calendar year. A matched-control cohort was created and the general non-SLE MEPS population was matched to MEPS SLE respondents by gender, age, region and MEPS reporting year using a 1:5 ratio.
From 2016 to 2018, 96 996 adults reported annual data in MEPS, of whom 154 respondents met the primary SLE definition, equivalent to 490 385 weighted number of adults with SLE. The prevalence of SLE was 195 (95% CI 149 to 242) per 100000, with greater prevalence observed in the US South, African-American/black and publicly insured people and females. SLE respondents reported limitations in physical function at 3 times greater rate (45% vs 15%; p<0.0001), higher rates of pain-limiting work (67% vs 39%; p<0.001) and feeling depressed 'nearly every day' (7% vs 2%; p<0.001) compared with non-SLE respondents. All-cause healthcare and prescription expenses were significantly higher in SLE respondents (US$17 270 vs US$8350 (p0.0001) and US$4512 vs US$1952 (p0.001), respectively, in 2018 US dollars).
Wide variation of SLE prevalence exists among patients of different regional, demographic and payer groups; SLE is associated with adverse quality of life, productivity and economic outcomes compared with non-SLE respondents.
系统性红斑狼疮（SLE）是一种慢性、多器官、自身免疫性疾病；然而，目前的患病率估计数据已经过时，且通常来自于不可推广的患者群体，并且真实世界中 SLE 患者的生活质量和患者报告的结果也没有得到很好的发表。本研究使用了医疗支出面板调查（MEPS），这是一个具有代表性的美国数据来源，涵盖了区域/支付者的代表性样本，以估计 SLE 的患病率，并与非 SLE 受访者相比，描述疾病负担。
使用 MEPS 在 2016 年至 2018 年的日历年内回顾性地进行了基于人群的调查数据，并对整个研究期间进行了汇总，这些数据经过了加权处理，以反映整个美国人口。主要纳入标准包括自我报告患有 SLE 并在日历年内有记录的 SLE 相关药物和/或风湿病就诊的成年人。创建了一个匹配对照队列，并通过性别、年龄、区域和 MEPS 报告年份，使用 1:5 的比例，将一般的非 SLE MEPS 人群与 MEPS SLE 受访者相匹配。
2016 年至 2018 年，96996 名成年人在 MEPS 中报告了年度数据，其中 154 名受访者符合主要的 SLE 定义，相当于有 490385 名加权的成年人患有 SLE。SLE 的患病率为每 100000 人中有 195 人（95%CI 149 至 242），在美国南部、非裔美国人/黑人以及公共保险人群和女性中观察到更高的患病率。SLE 受访者报告身体功能受限的比例是未患 SLE 受访者的 3 倍（45%比 15%；p<0.0001），疼痛限制工作的比例更高（67%比 39%；p<0.001），感觉每天都很沮丧（7%比 2%；p<0.001）。与非 SLE 受访者相比，SLE 受访者的全因医疗保健和处方费用明显更高（2018 年以美元计，SLE 受访者为 17270 美元，而非 SLE 受访者为 8350 美元（p<0.0001），SLE 受访者为 4512 美元，而非 SLE 受访者为 1952 美元（p<0.001））。
不同地区、人口统计学和支付者群体的患者 SLE 患病率存在很大差异；与非 SLE 受访者相比，SLE 与生活质量下降、生产力下降和经济结果不良相关。
